Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Roulston
D
D
Anastasi
J
J
Rudinsky
R
R
Nucifora
G
G
Zeleznik-Le
N
N
Rowley
J D
JD
McGavran
L
L
Tsuchida
M
M
Hayashi
Y
Y
D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy / Q000235:genetics*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D019070:Cell Lineage; D002648:Child; D002675:Child, Preschool; D002880:Chromosomes, Human, Pair 11 / Q000648:ultrastructure*; D002891:Chromosomes, Human, Pair 21 / Q000648:ultrastructure*; D002898:Chromosomes, Human, Pair 8 / Q000648:ultrastructure*; D003561:Cytarabine / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000235:genetics*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000139:chemically induced / Q000235:genetics*; D008942:Mitoxantrone / Q000008:administration & dosage; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics*; D009857:Oncogenes; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic
D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D001215:Asparaginase